Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Dianabol and Raloxifene Interaction: Avoid | Peptide Database

Compound Profiles Dianabol Oral Anabolic Steroid | Classic Mass Builder Dianabol exerts its effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle tissue. Its 17-a

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Dianabol

Oral Anabolic Steroid | Classic Mass Builder

Dianabol exerts its effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle tissue. Its 17-alpha-alkylated structure allows it to survive first-pass hepatic metabolism, enabling oral bioavailability but placing significant stress on the liver.

Raloxifene

Selective Estrogen Receptor Modulator | Gynecomastia & Bone Health

Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Dianabol with Raloxifene?

Combining Dianabol with Raloxifene is not recommended. Both Dianabol and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Dianabol and Raloxifene safe together?

This combination carries significant risk. Both Dianabol and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Dianabol and Raloxifene?

Both Dianabol and Raloxifene carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Dianabol and Raloxifene?

Dianabol has a half-life of ~4-6 hours and Raloxifene has a half-life of ~28 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

What's the ideal 5/5 vs 10/3 ratio for Tesa/IPA and when to use each?

5/5 (equal parts) provides balanced GH stimulation suitable for general recovery. The 10/3 (higher tesamorelin) variant emphasizes visceral fat loss and metabolic effects. Choose 5/5 for at…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

Shows beneficial long-term results in research following ischemic brain injury. Research demonstrates effects on restoration of injured nerve function. Regulates inflammatory response in the nervous system. Helps regulate immune function by reducing autoimmune reactions. Stimulates interleukin-2 expression for immune regulation. Restores balance between pro- and anti-oxidative processes. Addresses age-related CNS changes through bioregulation.

Source: peptide-db.com ↗

Community Research

Join others researching DNSP-11 — share findings, ask questions, and learn from real experiences DNSP-11 is an 11-amino acid peptide derived from the pro-domain of glial cell line-derived neurotrophic factor (GDNF). It was designed to capture the neuroprotective properties of GDNF while avoiding the limitations of the full-length protein, including poor blood-brain barrier penetration, off-target effects, and manufacturing complexity. Preclinical research demonstrates that DNSP-11 protects and stimulates dopaminergic neurons, making it a compound of significant interest for Parkinson's disease research and biohacking communities focused on dopamine system health. DNSP-11 acts on dopaminergic neurons through mechanisms distinct from full-length GDNF. Rather than binding to the canonical GFRalpha1/RET receptor complex, DNSP-11 appears to engage alternative signaling pathways to promote dopaminergic neuron survival, stimulate dopamine release, and protect against neurotoxin-induced damage. It enhances tyrosine hydroxylase expression (the rate-limiting enzyme in dopamine synthesis) and supports mitochondrial function in dopaminergic neurons.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

VIP has a very short half-life of approximately 2 minutes in blood, requiring careful dosing strategies. Subcutaneous or intravenous administration. Rapid degradation limits bioavailability; analogs like stearyl-Nle17-VIP (SNV) are 100-fold more potent. General use 50-100 mcg 1-2x daily SubQ or IV Research protocols 100-200 mcg As directed

Source: peptide-db.com ↗
Side effects

Common Side Effects

Limited data - primarily preclinical research Generally well-tolerated in animal studies

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →